Diabetes giant shows sign of bouncing back after excelling in 1st-qtr

3 May 2017

Danish diabetes giant Novo Nordisk (NOV: N) saw its share price decline by a massive 36% in 2016, but the roots of recovery are evident after it reported its first-quarter results for 2017, sending shares up by 6% in five hours of trading on Wednesday to 281.60 Danish kroner.

Compared to the first quarter of 2016, sales increased by 5% in kroner and 3% in local currencies to 28.5 billion kroner ($4.18 billion), beating the FactSet compiled consensus of 27.9 billion kroner.

Operating profit for the quarter was also ahead of expectations, rising 10% or 6% in local currencies to 13.5 billion kroner. Net profit rose by 7% to 10.2 billion kroner. Diluted earnings per share increased by 9% to 4.06 kroner.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK